Unknown

Dataset Information

0

General population reference values for the Functional Assessment of Cancer Therapy-Lung and PROMIS-29.


ABSTRACT:

Background

Therapeutic advances in lung cancer have turned attention toward patient-reported outcome measures (PROMs) as important clinical outcomes. The Functional Assessment of Cancer Therapy-Lung (FACT-L) is a common endpoint in lung cancer trials. This study calculated FACT-L reference values for the United States (US) general population.

Methods

Adults from the US general population (N = 2001) were surveyed between September 2020 and November 2020. Surveys contained 126 questions, including the FACT-L [36 items; FACT-G and four subscales (Physical Well-Being [PWB], Social Well-Being [SWB], Emotional Well-Being [EWB], and Functional Well-Being [FWB]) and the Lung Cancer Subscale (LCS), and a Trial Outcome Index (TOI)]. Reference values for each FACT-L scale were calculated with means for the total sample and separately for participants with: no comorbidities, COVID-19 as only comorbidity, no COVID-19.

Results

In the total sample, the reference scores were as follows: PWB = 23.1; SWB = 16.8; EWB = 18.5; FWB = 17.6; FACT-G = 76.0; LCS = 23.0, TOI = 63.7, and FACT-L Total = 99.0. Scores were lower for those reporting a prior diagnosis of COVID-19, especially for SWB (15.7) and FWB (15.3). SWB scores were lower than previous references values.

Conclusions

These data provide US general adult population reference value set for FACT-L. While some of the subscale results were lower than those found in the reference data for other PROMs, these data were obtained in a more contemporaneous time frame juxtaposed with the COVID-19 pandemic and may represent a new peri-pandemic norm. Thus, these reference values will be useful for future clinical research.

SUBMITTER: Mohindra NA 

PROVIDER: S-EPMC10278476 | biostudies-literature | 2023 Jun

REPOSITORIES: biostudies-literature

altmetric image

Publications

General population reference values for the Functional Assessment of Cancer Therapy-Lung and PROMIS-29.

Mohindra Nisha A NA   Peipert John Devin JD   Blum Steven I SI   Shaw James W JW   Penrod John R JR   Cella David D  

Cancer medicine 20230506 11


<h4>Background</h4>Therapeutic advances in lung cancer have turned attention toward patient-reported outcome measures (PROMs) as important clinical outcomes. The Functional Assessment of Cancer Therapy-Lung (FACT-L) is a common endpoint in lung cancer trials. This study calculated FACT-L reference values for the United States (US) general population.<h4>Methods</h4>Adults from the US general population (N = 2001) were surveyed between September 2020 and November 2020. Surveys contained 126 quest  ...[more]

Similar Datasets

| S-EPMC9931172 | biostudies-literature
| S-EPMC8427163 | biostudies-literature
| S-EPMC10988832 | biostudies-literature
| S-EPMC11802291 | biostudies-literature
| S-EPMC5015641 | biostudies-literature
| S-EPMC7408671 | biostudies-literature
| S-EPMC4664440 | biostudies-literature
| S-EPMC6928422 | biostudies-literature
| S-EPMC11666766 | biostudies-literature
| S-EPMC6764695 | biostudies-literature